SUBSCRIBE
SUBSCRIBE
News   Drug Development

Exelixis, Inc. Reports Updated Phase 2 Data for XL184 in Patients With Recurrent Glioblastoma to Be Presented at American Society of Clinical Oncology

March 17, 2010 | 
1 min read

(RTTNews) - Exelixis, Inc. (EXEL: News ) on Thursday reported promising interim data from an ongoing phase 2 trial of XL184 in patients with recurrent glioblastoma, the most common and aggressive form of brain cancer.

Clinical research Phase II
Exelixis, Inc.
MORE ON THIS TOPIC
Beautiful colorful unpeeled peanut pattern on a light blue background. Flat lay arrangement, top view.
Immunology and inflammation
First Head-to-Head Study Cements Roche’s Xolair as Food Allergy Leader
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Human Nose Like Worker Is Going To Work. Vector Collage Illustration Against The Background Of The City
Immunology and inflammation
AstraZeneca, Amgen’s Phase III Win Strengthens Case for Tezspire Expansion
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
3D illustration of an RNA molecule
Cardiovascular disease
Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner
February 28, 2025
 · 
2 min read
 · 
Tristan Manalac
mRNA leaves the nucleus, it moves to a ribosome 3d rendering
Opinion
How mRNA Can Help Bridge the Innovation Gap in Rare Disease
February 28, 2025
 · 
3 min read
 · 
Kyle Holen